IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$9.20 USD
-0.07 (-0.76%)
Updated May 14, 2024 04:00 PM ET
After-Market: $9.23 +0.03 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 41 - 60 ( 84 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Although Early, IGMS-2323 Results Appear to Underwhelm; Lowering PT to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-2323 ORR Snapshot Modest, but Higher Doses Confound Picture
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Updated IGM-2323 Results at ASH; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Updates Across Broadening Pipeline;Upgrading to OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; IGM-2323 Dose Escalation Complete; Data for Two Programs Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-6268 Entering Clinic in 3Q21 for COVID-19; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Licensing Deal for IgM Antibody for COVD-19; Clinical Entry Expected in Q3:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Correction: Q1 Financials; Many Hands Make Light Work - Programs Remain on Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Data Could Derisk IGM-2323; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; IGM-2323 Update; IGM-8444 Clears Critical Dose Level
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Market Risks Appear Mitigated; IGM-2323 Update Near-Term; Raising PT to $114
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM In-Licenses Birinapant For IGM-8444 Combination; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R